Uterine leiomyosarcoma is a lethal cancer with few therapeutic targets. In response to the high rate of local recurrence, we initiated a phase 2 trial at Stanford investigating intra-abdominal chemotherapy at the time of surgery. 

 

In the wake of this trial, we are incorporating Stanford’s technological and computational strengths to generate the world’s largest collection of uterine leiomyosarcoma findings at the single cell resolution. These data will then be incorporated into cutting edge pharmacogenomic pipelines to identify therapeutic targets, which are then validated in organoid models. We aim to use this approach as a model to accelerate the discovery of new treatments for rare tumors.